Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mediomics has received a $997,251 phase II SBIR contract from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services to develop a fully automated in-process analyzer.
Subscribe to our email newsletter
Using Pincer platform, Mediomics will develop antigen-specific assays for antibody titer, affinity, glycosylation and aggregation and is also expected to culminate with beta-testing by Gallus Biopharmaceuticals.
The company will collaborate with industry partners, Washington University and Gallus Biopharmaceuticals to develop applications for its Pincer platform.
Mediomics president Yie-Hwa Chang said the grant will help to move the cheaper, faster screening technology into mainstream applications.
"We expect the availability of the molecular PINCER®-based automated in-process analyzer will displace cumbersome benchtop instruments and gain acceptance for use in biologics production and food pathogen detection," Chang added.